Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419. The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States.

United States

Malvern, PA, USA

Galera Therapeutics

Healthcare

Correlation Ventures

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Correlation Ventures Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Correlation Ventures network as they come up.

You can always update this information later.

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Correlation Ventures company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Companies you’ll love to work for